Race to report: are vascular endothelial growth factor genetic polymorphisms associated with outcome in advanced breast cancer patients treated with Paclitaxel plus bevacizumab?
- PMID: 19188671
- DOI: 10.1200/JCO.2008.20.6359
Race to report: are vascular endothelial growth factor genetic polymorphisms associated with outcome in advanced breast cancer patients treated with Paclitaxel plus bevacizumab?
Erratum in
- J Clin Oncol. 2009 Dec 1;27(34):5859. Min-Han, Tan [corrected to Tan, Min-Han]; Seng, Tan Chuen [corrected to Tan, Chuen Seng]; Yen, Lim Wei [corrected to Lim, Wei Yen]
Comment on
-
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.J Clin Oncol. 2008 Oct 1;26(28):4672-8. doi: 10.1200/JCO.2008.16.1612. J Clin Oncol. 2008. PMID: 18824714 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
